NRX Pharmaceuticals, Inc. Derivative, Gain (Loss) on Derivative, Net
NRX Pharmaceuticals, Inc. (NRXP) reported Derivative, Gain (Loss) on Derivative, Net of -$9.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeGainLossOnDerivativeNet · last filed 2024-05-14
- NRX Pharmaceuticals, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2024-03-31 was -$9.00K, a 175.00% decline year-over-year.
- NRX Pharmaceuticals, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2023-12-31 was -$7.00K, a 136.84% decline year-over-year.
- NRX Pharmaceuticals, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2023-09-30 was $26.00K.
- NRX Pharmaceuticals, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2023-06-30 was -$11.00K, a 109.48% decline year-over-year.
- NRX Pharmaceuticals, Inc. derivative, gain (loss) on derivative, net for fiscal 2023 was $20.00K, a 92.16% decline from fiscal 2022.
- NRX Pharmaceuticals, Inc. derivative, gain (loss) on derivative, net for fiscal 2022 was $255.00K, a 84.93% decline from fiscal 2021.
- NRX Pharmaceuticals, Inc. derivative, gain (loss) on derivative, net for fiscal 2021 was $1.69M.
- NRX Pharmaceuticals, Inc. derivative, gain (loss) on derivative, net for fiscal 2020 was -$655.10K.
| Period end | Derivative, Gain (Loss) on Derivative, Net 3 month | Derivative, Gain (Loss) on Derivative, Net 3 month as first filed | Derivative, Gain (Loss) on Derivative, Net 6 month | Derivative, Gain (Loss) on Derivative, Net 6 month as first filed | Derivative, Gain (Loss) on Derivative, Net 9 month | Derivative, Gain (Loss) on Derivative, Net 9 month as first filed | Derivative, Gain (Loss) on Derivative, Net 12 month |
|---|---|---|---|---|---|---|---|
| 2024-03-31 | -$9.00K 10-Q · filed 2024-05-14 | -$16.00K derived: sum of 2 quarters · filed 2024-05-14 | $10.00K derived: sum of 3 quarters · filed 2024-05-14 | -$1.00K derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2023-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $19.00K derived: sum of 2 quarters · filed 2024-03-29 | $8.00K derived: sum of 3 quarters · filed 2024-03-29 | $20.00K 10-K · filed 2024-03-29 | |||
| 2023-09-30 | $26.00K 10-Q · filed 2023-11-14 | $15.00K derived: sum of 2 quarters · filed 2023-11-14 | $27.00K 10-Q · filed 2023-11-14 | $46.00K derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2023-06-30 | -$11.00K 10-Q · filed 2023-08-14 | $1.00K 10-Q · filed 2023-08-14 | $20.00K derived: sum of 3 quarters · filed 2024-05-14 | -$17.00K derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2023-03-31 | $12.00K 10-Q · filed 2024-05-14 | $31.00K derived: sum of 2 quarters · filed 2024-05-14 | -$6.00K derived: sum of 3 quarters · filed 2024-05-14 | $110.00K derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$18.00K derived: sum of 2 quarters · filed 2024-03-29 | $98.00K derived: sum of 3 quarters · filed 2024-03-29 | $255.00K 10-K · filed 2024-03-29 | |||
| 2022-09-30 | -$37.00K 10-Q · filed 2023-11-14 | $79.00K derived: sum of 2 quarters · filed 2023-11-14 | $236.00K 10-Q · filed 2023-11-14 | $1.10M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $116.00K 10-Q · filed 2023-08-14 | $273.00K 10-Q · filed 2023-08-14 | $1.14M derived: sum of 3 quarters · filed 2023-08-14 | -$15.39M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | $157.00K 10-Q · filed 2023-05-15 | $1.03M derived: sum of 2 quarters · filed 2023-05-15 | -$15.51M derived: sum of 3 quarters · filed 2023-05-15 | $1.85M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $869.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$15.67M derived: sum of 2 quarters · filed 2023-03-31 | $1.69M derived: sum of 3 quarters · filed 2023-03-31 | $1.69M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | -$16.54M 10-Q · filed 2022-11-14 | -$260.24K 10-Q · filed 2021-11-15 | $822.00K derived: sum of 2 quarters · filed 2022-11-14 | $823.00K 10-Q · filed 2022-11-14 | $1.21M 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | $17.36M 10-Q · filed 2022-08-15 | $1.47M 10-Q · filed 2021-08-16 | $17.36M 10-Q · filed 2022-08-15 | $1.47M 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | -$658.23K 10-Q · filed 2021-05-21 | ||||||
| 2020-12-31 | -$655.10K 10-K/A · filed 2021-05-14 | ||||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-21 | ||||||
| 2019-12-31 | $0.00 10-K/A · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |